NASDAQ · Biotechnology

Alterity Therapeutics Limited (ATHE) Stock

$4.70 -5.62% NASDAQ: ATHE Healthcare

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease.

Valuation

MetricValue
Price$4.70
Market Cap$42.60M
P/E Ratio-6.89
P/B Ratio2.12
P/S Ratio32.06
EPS (TTM)$-0.64
52-Week High$7.00
52-Week Low$2.66
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-30.19%
ROA-25.63%
ROCE-37.08%
Gross Margin96.82%
Operating Margin-525.58%
Net Margin-380.65%
Debt/Equity0.00
Current Ratio21.98

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$5.0M$4.0M$4.0M$5.0M
Operating Profit$-15.0M$-16.0M$-15.0M$-20.0M$-15.0M
Net Profit$-15.0M$-13.0M$-14.0M$-19.0M$-12.0M
EPS$-5.40$-3.18$-3.42$-3.12$-1.14
Op Margin-349.8%-302.6%-373.7%-487.7%-268.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$34.0M$41.0M$27.0M$19.0M$46.0M
Total Liabilities$3.0M$6.0M$5.0M$5.0M$4.0M
Cash$28.0M$35.0M$16.0M$13.0M$33.0M
Borrowings$0$0$0$0$0

Latest News

US to Impose 25% Section 301 Tariff on Certain Brazilian Imports MT Newswires · Jul 17, 2026 Fed's Jefferson Open to Rate Hike If Inflation Persists MT Newswires · Jul 17, 2026 Benchmark (BHE): Buy, Sell, or Hold Post Q1 Earnings? StockStory · Jul 17, 2026 Rapidus and Cadence Partner on Agentic AI for Advanced SoC Design Business Wire · Jul 17, 2026 Hazardous Canadian wildfire smoke choking millions in US AFP · Jul 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$-12.0M$-20.0M$-13.0M$-11.0M
Investing Cash Flow$0$0$0$0$-7.0M
Financing Cash Flow$-2.0M$-1.0M$0$-1.0M$-3.0M
Net Cash Flow$19.0M$7.0M$-19.0M$-3.0M$21.0M
Free Cash Flow$-17.0M$-12.0M$-20.0M$-13.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA-3.67
FCF Yield-1.92%
Quick Ratio21.98
Interest Coverage0.00
Return 1Y-8.91%
Return 3Y60.41%
Return 5Y-64.93%

Ownership

Insiders Held0.00%
Institutions Held1.78%
Institutions Float Held1.78%
Institutional HolderSharesReport Date
Twin Lakes Capital Management, LLC139,2582026-03-31
HB Wealth Management, LLC58,4602026-03-31
Morgan Stanley58,3822026-03-31
Greenleaf Trust32,0002026-03-31
Citadel Advisors Llc20,0772026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.70 +0.59% -1.54 $33.45M 0.00%
BTAIBioXcel Therapeutics, Inc. $0.87 +2.30% -0.13 $26.77M 0.00%
DYAIDyadic International, Inc. $1.17 -1.68% -5.59 $42.63M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About Alterity Therapeutics Limited

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Alterity Therapeutics Limited is headquartered in AU.

Alterity Therapeutics Limited (ATHE) stock trades at $4.70 with a market capitalization of $42.60M. The stock is valued at a price-to-earnings (P/E) ratio of -6.89, price-to-book of 2.12, price-to-sales of 32.06. Over the past 52 weeks the stock has ranged between $2.66 and $7.00, and currently trades 32.9% below its 52-week high.

On profitability, Alterity Therapeutics Limited generates a return on equity (ROE) of -30.19%, return on capital employed of -37.08%, an operating margin of -525.58%, a net profit margin of -380.65%.

Official website: alteritytherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides